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In the present review, we have summarized and analyzed the literature data concerning cooperation between
multifunctional proteins, the components of plasminogen/plasmin system and actin. The mechanisms underlying
intermolecular interactions and the role of plasminogen kringle domains in protein-protein recognition are
reviewed. A particular attention is paid to extracellular actin that serves as a surface protein of plasma mem-
brane in various cells. A putative role of surface actin as the universal «non-hemostatic» center of plasminogen
activation is discussed. The exposition of cytoskeletal actin on the outer surface of cellular membrane is thought to
be a phenomenon, which is involved in both normal cell functioning and development of pathologies. In parti-
cular, the mechanism of plasminogen fragmentation on the surface of cancer cells mediated by actin, which re-
sults in generation of endogenous suppressors of tumor growth and metastazing (angiostatins), is described. It
has been acknowledged that the plasminogen/plasmin system in concert with surface actin regulates releasing
biologically active substances, e. g. catecholamines. The comprehensive assessment of plasminogen/plasmin
system and surface actin exposition is proposed to be a criterion of functional status of cells and can be used as a
diagnostic parameter at various pathologies.
Keywords: multifunctional proteins, plasminogen/plasmin sys- tem, actin.
The term “multifunctionality” is used to denote the abi-
lity of a protein to perform several alternative func-
tions. The availability of a great number of multifun-
ctional proteins, remarkable for multicompartmenta-
tion and “ubiquity”, brings up a reasonable issue of the
interaction of such molecules and the physiological
role of this cooperation. Countless studies show intera-
cting ability for the whole spectrum of multifunctional
proteins (cytoskeleton components, glycolytic enzy-
mes, kinases, transcription factors, growth factors,
chaperons, transmembrane proteins, proteins of extra-
cellular matrix), previously considered to be functio-
nally separate [1]. Among the proteins, “novel” functi-
ons of which are actively investigated, special attention
is focused on actin and components of plasminogen/
plasmin system (Pg/Pm). Until recently, the role of
actin was limited to its participation in the functioning
of cytoskeleton and contractile apparatus of cell [2].
However, there are rather unexpected reports about
actin exposure by some cells on the external surface of
the plasmatic membrane, though the functional signi-
ficance of this phenomenon remains to be elucidated
[3–5]. It is thought that actin of the cellular surface is
capable of performing some receptor functions, inte-
racting with the components of plasma or extracellular
matrix [6]. Some of the proteins, which are recognized
and bound by actin, are the components of Pg/Pm sys-
tem [7]. Pg is a zymogene of serine proteinase Pm, the
principal function of which is to cleave fibrin clots [8].
In addition to blood plasma, the components of Pg/Pm
system are present in intracellular medium of tissues
and involved in a number of normal and pathophysio-
logical processes, regulating activity of various cells
[9–10].
Special attention is paid to products of limited pro-
teolysis of Pg, known as angiostatins (AS), which
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demonstrate powerful angiostatic and anti-inflamma-
tory effects, thus inhibiting pathological neovasculari-
zation and metastasis. Mainly the formation of AS in
organism occurs on the surface of the plasma membra-
ne of cells, including tumor cells [11, 12], and surface
actin functions as a matrix for the Pg activation and
further AS generation. Exposure of actin by malignant
cells is considered to be the defense mechanism, aimed
to inhibit tumor growth and metastasis [7]. The investi-
gation of the molecular mechanisms of AS formation
and the regulation of this process may be useful for ela-
boration of more efficient approaches to the therapy of
malignant neoplasms and other disorders, associated
with vascular pathologies.
There are reasons to assume a role of extracellular
actin in normal physiological processes. The list of
cells, exposing actin on the external surface of the
plasma membrane, is rather long: B-lymphocytes [3],
endotheliocytes [13], platelets [14], monocytes [4],
fibroblasts [15], pericytes [16], smooth muscle cells
[17], sperm cells [5]. There are considerable arguments
that the exposure of outer surface actin depends on the
physiological state of the cell. For instance, transfor-
med or mitogen-stimulated lymphocytes expose much
more surface actin than intact lymphocytes and the ex-
tracellular actin is only on B-, not T-lymphocytes [3]. It
is assumed that platelets are capable of exposing actin
during agonist-induced activation [14]. In contrast to
abovementioned examples, resting monocytes U-937
expose surface actin, whereas their activation leads to
the disappearance of this protein from the membrane
surface.
Taking into consideration wide distribution of ac-
tin, one may predict that on the surface of cells this pro-
tein may serve as a universal modulator of the Pg/Pm
system activity.
Using the model of catecholamine-producing cells,
it was previously shown that extracellular actin media-
tes the formation of Pm and ensures the participation of
proteinase in the regulation of hormone release [18].
The analysis of literature data indicates significance
of the interaction between actin and proteins of the
Pg/Pm system for the regulatory and compensatory me-
chanisms of organism. To the best of our knowledge,
the present report is the first attempt to systemize the
data about the molecular mechanisms of actin–Pg/Pm
interaction, to generalize the physiological significance
of this cooperation, and to define the perspectives of
further studies and practical application of their results
for diagnostics and therapy of a great number of patho-
logies.
Actin and components of the Pg/Pm system are
multifunctional proteins. The name “actin” is used to
denote the whole family of proteins, encoded by indi-
vidual genes. One of the main peculiarities of actin is a
high degree of structural conservatism. The differences
between aminoacid sequences of various actins of the
same species and diverse species are scarce: they are
limited to about 25 aminoacid replacements. Actin is a
“ubiquitous” protein, since it is synthesized by all
eukaryotic cells, besides, it is the most common protein
for their majority (10–15 % of the total amount of
protein) [19].
It is well acknowledged that the principal functions
of actin (contractile and cytoskeletal) are performed
due to its existence in two forms, differing by physical
and chemical properties and present in a cell in dynamic
equilibrium. Globular actin (G-form) is a one-chain
two-domain polypeptide with the molecular mass of
about 42 kDa, the isoelectric point of about 5.4 and the
length of 375 aminoacid residues. The G-actin polyme-
rization leads to the formation of labile cytoskeleton
structures – actin filaments, and polymerized actin in
their composition is called F-actin.
At present, six actin isoforms have been identified
in the cells of vertebrates, differing by the value of iso-
electric point and the stability of filament structures.
The synthesis of isoactins is tissue-specific and regu-
lated at the level of expression of corresponding genes.
For instance, the myofibrils of skeletal muscles, smooth
muscles and heart contain different -isoforms of actin,
while the microfilaments of cytoskeleton of non-mus-
cle cells contain - and -actins. There are reasons to
assume that the specificities of segregation and com-
partmentation of actin isoforms in the cells of different
histotypes indicate their functional non-equivalence
[20].
Recent studies proved that due to unique physical
and chemical properties, specificities of synthesis and
compartmentalization, actin is able to perform much
wider spectrum of functions than it used to be consi-
dered before. Actin is involved in regulation of activity
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of ion channels [21], transmission of intracellular signal
to the genome [22], transport of mRNA and transcri-
ption [23], transfer of mediators [24], and regulation of
enzyme activity [25]. Impairments of the processes of
assembly–disassembly of the cytoskeleton actin struc-
tures lead to cell dysfunction and even their malignant
transformation [26]. Some pathogenic bacteria use
actin microfilaments to invade the host cell [27]. The
variety of morphofunctional types of actin in cell is not
limited to the monomer form, polymerized in filaments
and associated with plasma membrane. There is a grow-
ing body of information describing exposure of diffe-
rent actin isoforms on the outer surface of the plasma
membrane [1]. It is noteworthy that the surface actin
maintains physical connection with the actin micro-
filaments of cell cytoplasm, and the translocation of
actin onto the membrane surface depends on the
functional state of a cell [28, 29].
Actin in both monomer form and polymerized sta-
te demonstrates high reaction ability to interact with a
number of cell molecules: other actin subunits, actin-
associated proteins, enzymes, nucleotides, ions, etc.
[29]. It was established that actin binds to some proteins
of blood plasma with high affinity; thereby, special
attention is paid to the components of the Pg/Pm system
[7, 30]. Pg is an inactive zymogene of serine proteinase
Pm. Pg is a one-chain glycoprotein of 92 kDa, consis-
ting of 792 aminoacid residues and containing about 2
% carbohydrates. Pg circulates in plasma in the form of
native proenzyme with NH2-terminal residue of gluta-
mic acid (Glu-Pg), the concentration of which is about
0.15 g/l [30, 31]. Pm-mediated limited proteolysis of
the latter yields partially degraded Pg molecule, or
Lys-Pg, whose conformation is different from that of
native Pg. It was determined that Lys-Pg is more
readily transformed into Pm compared to Glu-form
[32]. Pg becomes an active enzyme via the cleavage of
peptide bond Arg560-Val561. The process of Pm
transforming into Pg and the enzyme activity in the
organism are under the strict control of a variety of
activators and inhibitors. The conversion Pg > Pm in
the organism is mainly performed by the tissue activa-
tor Pg (t-PA) and the activator of urokinase type
(u-PA). There are also exogenous activators, strepto-
kinase and staphylokinase being the most powerful
ones. A specific endogenous inhibitor 2-antiplasmin
is a negative effector for Pm. Also the formation of Pm
from proenzyme is inhibited by Pg activators (PAI-1,
PAI-2, PAI-3) [8, 33].
A remarkable feature of the Pg/Pm structure is the
presence of five highly-homologous three-loop struc-
tures, so called kringles. Each of five domains consists
of 80 aminoacid residues on average and is stabilized
by three disulfide bonds. Kringles contain lysine bin-
ding sites (LBS), which mediate the interaction of
Pg/Pm with other proteins, including fibrin, thus ensu-
ring the orientation of the active enzyme center regar-
ding some peptide bonds of the substrate molecule [34].
Liver is the main organ, in which Pg is synthesized
and released to plasma. Besides hepatocytes, mRNA of
Pg was discovered in the cells of adrenal glands, kid-
neys, brain, testis, heart, lungs, uterus, spleen, thymus,
intestines [35].
A wide range of organism structures, the cells of
which synthesize Pg, is the basis of the assumption that
this protein plays the role of both the circulating pre-
decessor of active protease of plasma, but also the
signaling molecule, the functioning of which might be
associated with some cellular or subcellular structures.
The molecular mechanisms of Pg/Pm involvement in
the processes of cellular signaling and realization of
regulatory functions are extensively explored [36, 37].
Due to unique properties of kringle domains of Pg
molecule and its capacity of conformational motility,
the interaction of this protein with different ligands
becomes possible. To date, a great number of potential
plasminogen receptors (-enolase, proteins of integrin
family, anexin 2, cytokeratin 8, tetranectin, ganglio-
sides) on the surface of plasma membranes of various
cells (monocytes, macrophages, platelets, endotheliocy
tes, fibroblasts, sympathoadrenal system cells, sperm
cells, etc.) have been identified [9, 38]. A special place
in this list belongs to extracellular actin, since this
protein plays a key role in modulating the activity of
Pg/Pm system on the cell surface. The interaction of Pg
with receptor molecules may have different conseque-
nces, leading either to signal transfer inside the cells, or
to the activation of zymogene, however, this issue re-
quires further studies.
The components of Pg/Pm system are involved in
the pathogenesis of such pathologies as tumor growth
[39], atherosclerosis [40], autoimmune diseases [41],
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diabetes [42], Alzheimer’s disease [43], inflammation
[44], and the role of Pg/Pm system in the pathological
processes is ambiguous. On the one hand, on the cell
surface Pg may be converted into Pm, which stimulates
monocytes and macrophages, thus activating the
inflammatory reaction, and Pm-induced degradation of
extracellular matrix proteins promotes angiogenesis,
invasion of cancer cell and metastasis [45, 46]. On the
other hand, Pm, anchored on the membrane binding
site, may undergo autoproteolysis with the formation of
products of limited hydrolysis – AS [47]. In contrast to
Pg, AS inhibit the proliferation and migration of
endotheliocytes, thus demonstrating their angiostatic
activity, induce apoptosis in malignant cells and serve
as anti-inflammatory agents [48, 49]. The authors of the
study [50] established that surface -actin is an
exclusive center of Pg>Pm>AS conversion among all
known receptors. Surface actin seems to mediate the
realization of an important link of defense mechanisms
of the organism, aimed to inhibit tumor growth. Further
studies are required to investigate the presence of a
positive correlative connection between the exposure
of actin on the surface of tumor cells and the lifespan of
patients with cancer. The investigations of the
mechanisms of actin–Pg/Pm interaction and further
generation of AS, the regulation of these processes,
their role in pathologies associated with neovasculari-
zation, inflammatory reactions, tissue malignancy, are
vital for the elaboration of novel diagnostic and
therapeutic approaches.
Interaction between the Pg/Pm system and
extracellular actin.Actin circulates in blood plasma of
humans and animals; for different pathologies,
accompanied by the damage of tissues and cell
destruction, its concentration increases to several µM,
therefore, damaged cells are considered to be the main
source of circulating actin [50]. However, according to
the data of the authors [51], some cultivated cell types,
in particular, embryonic myocytes, secrete actin into
the nutrient medium without loss of their viability.
Similarly, the cells are assumed to secrete persistently
the respective actin isoforms into the blood flow at
normal functioning. The extracellular actin might play
a role in the regulation of the activity of plasma pro-
teins. The organism has a protein system that controls
actin concentration in plasma. It includes gelsolin of
plasma and vitamin D-binding protein, or Gc-globulin,
that are necessary for defragmentation of actin fila-
ments, binding of monomer polypeptides and, finally,
removing actin from the circulation [52]. Some of pla-
sma proteins, capable of interacting with actin with
high affinity, are Pg/Pm and t-PA (according to the data
of different researchers, the dissociation constant Kd of
the actin-Pg complex is 70–140 nM, Kd of actin–t-PA –
0.55 µM) [7, 53]. However, the physiological signifi-
cance of this interaction remains to be determined. The
authors of [54] showed that the binding of monomer
actin to Pm leads to inhibition of its catalytic activity
and/or modification of substrate specificity and a dec-
rease in the rate of fibrin clot cleavage. On the other
hand, actin stimulates t-PA-mediated generation of Pm
from both Glu- and (with even higher rate) Lys-Pg. In
the presence of actin, a decrease in Km value for
Glu-Pg>Pm reaction, catalyzed by t-PA (enzyme, in
turn containing two kringle domains) was obsereved.
The mechanism of this process is the interaction of Pg
and t-PA on the surface of actin (or actin filament),
which is similar to the formation of so called triple
complex on the surface of a fibrin matrix. The binding
of Pg and t-PA to actin occurs via LSB of kringles of
both proteins. A lysine analogue, 6-aminohexanoic
acid (6-AHA), inhibits actin-mediated generation of
Pm from Pg with the participation of t-PA, and this fact
confirms the abovementioned mechanism. In contrast
to polymerized fibrin, which is hydrolyzed by Pm
activated on its surface, actin is not a “suitable”
substrate for Pm. In vitro experiments on the hydrolysis
of actin by pure Pm demonstrated that the enzyme is
capable of limited proteolysis of actin by cleaving
single peptide bond in the position Lys373-Cys374.
Compared to the native molecule, a partially degraded
actin binds Glu-Pg with higher affinity. It is assumed
that this effect is possible due to the change in the actin
molecule conformation after its hydrolysis by Pm, in
particular, the orientation of lysine residues and repre-
sentation of the additional binding center – C-terminal
residue Lys, which effectively interacts with kringle
domains of Pg molecule [53]. Based on these data, one
may state that the circulating actin lowers the potential
of the fibrinolytic system. Firstly, it binds Pg with high
affinity and accelerates its transformation into Pm, thus
depleting zymogene pool in plasma. Secondly, the
enzyme in the stable complex with actin appears to be
inactive, interrupting its participation in the fibrinolytic
process. It should also be noted that there are no lite-
rature data on any case of the autoproteolysis of Pm,
formed from Pg in t-PA-dependent manner and bound
to extracellular actin.
Appearance of actin in plasma in the amounts,
exceeding the capacity of the defense system, may have
deleterious consequences for the organism. It is espe-
cially harmful for the functioning of microvessels. The
cases of rapid fibrin clot formation in microvessels in
the presence of large amount of extracellular actin have
been documented [54]. The significance of the inte-
raction of two protein systems in the pathophysiolo-
gical processes is emphasized due to their “ubiquity”.
The inflammation of any localization leads to the vas-
cular endothelium cell death, accompanied by the
release of actin and Weibel-Palade bodies and subse-
quent increase in the local concentration of t-PA in the
damaged place [55]. In turn, the circulating actin is ca-
pable of enhancing the effects of inflammation media-
tors, and thus promoting the the vicious circle forma-
tion. Therefore, the actin-stimulated generation and
further inactivation of Pm may make a considerable
contribution into the hemostasis disorders, observed
during sepsis, inflammation, and tissue damage. It will
be demonstrated below that actin of plasma and extra-
cellular actin, situated on the outer surface of plasma
membrane, make different impact on both the system of
Pg activation and Pm activity, including the capability
of the latter to undergo autoproteolysis resulting in the
formation of AS.
Interaction of Pg/Pm system with actin on the
surface of cancer cells: the mechanism of AS
generation. The components of cascade of Pg acti-
vation, first of all, u-PA and its receptor (u-PAR), are
exposed in excessive amounts (in comparison with
normal cells of the same histotype) on the outer surface
of the plasma membrane of some malignant cells [47].
Participation of these proteins in the processes of tumor
growth and metastasis has been proved experimentally
[56]. It was established that parallel hyperexpression of
u-PA and u-PAR correlates with the aggressiveness
degree of breast cancer [57]. The comparison of the
profiles of Pg binding to normal and neoplastic cells
demonstrated that this protein is more efficient in
binding to the membranes of malignant cells, especially
the ones with high metastatic potential [58]. Key mo-
lecular events on the surface of malignant cells are
highly efficient interaction of Pg, the change in its con-
formation and further conversion into Pm [47]. The
proteins, exposing C-terminal residues of Lys, like cy-
tokeratin 8 and -enolase, were considered as possible
candidates for Pg binding. However, these receptors
appeared to be responsible for the binding of only 10 %
Pg on the cell surface, which was demonstrated, for in-
stance, in the experiments with lymphoma U937 cells
[59]. Further u-PA-dependent activation of Pg leads to
the appearance of membrane-associated active Pm,
catalyzing the degradation of components of extra-
cellular matrix, which is required for the invasion of
malignant cells and metastasis. The pool of endothelial
and malignant cells, containing membrane-associated
Pm, has 3-fold higher invasive potential compared to
Pm-negative cells [60]. It was demonstrated that the
interaction of Pm with integrin receptor v on the
surface of endotheliocytes stimulates migration of these
cells [44]. The alternative mechanism of realization of
proangiogenic properties by Pm is the induction of
angiogenesis factors, in particular, VEGF-C and
VEGF-D, by means of activation of the corresponding
propeptides [61]. There are a number of malignant or
transformed cells, capable of exposing actin on the
external surface of the plasma membrane, which may
potentially serve as an additional center of Pg binding
and activation [59].
Are cancer cells able to adsorb Pg via surface actin
and what properties do they acquire due to the con-
version of zymogene into Pm? These questions seem to
be rather reasonable taking into consideration extreme-
ly important and somewhat unexpected observations. It
turned out that 50 % of the total amount of Pg, bound to
the surface of a malignant cell, are localized on actin
[13]. Moreover, in cultivating conditions, plasmin acti-
vity on the surface of transformed cell, which are cha-
racterized by high density of extracellular membrane-
bound actin, decreased by 75 % for a few minutes after
Pg had been converted into Pm [59]. This observation
may be explained by rapid inactivation of Pm by 2-
antiplasmin and/or autoproteolysis of Pm, and, as a
result, the dissociation of its complex with actin.
However, it is well known that Pm, formed on the fibrin
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clot or the cell surface, is protected from the 2- anti
plasmin-induced inactivation [62]. Therefore, this inhi-
bitor cannot have considerable influence on the inhi-
bition of plasmin activity in the fraction of membra-
ne-bound proteins. The second assumption proved to
be true: the main cause of plasmin activity loss is phy-
sical dissociation of Pm from the surface of the plas-
matic membrane due to autoproteolysis.
The data of the inhibitory analysis using lysine and
its analogue (6-AGK) demonstrate that Pg/Pm interact
with actin through LBS of kringle domains. In turn,
lysine residues in the actin molecule are involved in the
interaction with Pg/Pm in positions 61, 68 and 113,
which are conservative and occur in all known actin
isoforms. Residue Lys61 is the most important in the
intermolecular recognition of Pg/Pm–actin, since it is
situated on the surface of the actin globule. Failure of
Pg/Pm binding to actin was observed when lysine re-
sidues in the positions 61 and 68 of actin molecule were
substituted with arginine, while the synthetic peptide-
analogue of the fragment of polypeptide actin chain that
comprises aminoacid residues 55–69, inhibits the reac-
tion of Pm autoproteolysis in the presence of actin in
competitive manner.
The following observation is particularly important
to understand the mechanism, by which actin is invol-
ved in Pm cleavage. As it turned out, the abovemen-
tioned short peptide-analogue of the actin chain in the
cell-free medium is efficient in binding to Pm, but it
does not stimulate the autoproteolysis reaction. Further
experiments demonstrated that Pm self-cleavage requi-
res an intact molecule of actin, which is important,
firstly, as a matrix for conformational changes of Pm
molecule, vital for further reaction and, secondly, as a
reducing agent. The physicochemical properties of ac-
tin as well as the specificities of its spatial structure are
ideal for optimal orientation of groups in the active
center of Pm and its further cleavage. The analysis of
the products of Pm autoproteolysis, bound to the sur-
face -actin on the membrane of three types of human
malignant cells, PC-3 (prostate cancer), HT1080 (fi-
brosarcoma) and MDA-MB231 (breast cancer),
revealed that the hydrolysis of the peptide bond in the
position Arg530–Lys531 of Pm molecule leads to the
releasing of the fragment with the truncated fifth
cringle, i.e. K1-4 plus 85 % of cringle 5, often called
K1-4,5 (AS 4,5). It implies that the intact cringle 5 is
responsible for the interaction of Pg/Pm with actin,
since the formed AS fails to interact with actin [7, 47].
The role of the fifth cringle in the intercellular recog-
nition needs further experiments, because the reaction
centers of cringle 5 have higher affinity to lysine resi-
dues, located inside the polypeptide chains compared to
cringles 1, 2 and 4 [63]. After fragment K1-4,5 is relea-
sed from the cell surface, it enters the systemic blood
circulation [7]. It is known that, similarly to other pro-
teolytic fragments of Pg/Pm-AS, containing different
number of cringles (K1-3, K2-3, K1-4, K1-5), K1-4,5
has potent antiangiogenic activity, due to which it inhi-
bits neovascularization and tumor metastasis. In addi-
tion, AS may cause direct antitumor activity, thus indu-
cing apoptosis of cancer cells [11, 48, 49]. Therefore,
the product of autoproteolytic degradation of Pm is cha-
racterized by physiological activity, which is opposite
to that of the initial molecule.
The autoproteolysis of Pm with the formation of AS
may be considered as a four-stage process, the main sta-
ges of which are illustrated in Fig. 1. It is noteworthy
that the sequence of presented events could be possible
only in case of simultaneous presence and close spatial
location of all the required components of Pg acti-
vation: surface actin, u-PA and respective receptor
(u-PAR). Current experimental data indicate the occur-
rence of these molecules in the amounts, required for
AS generation, only on the surface of some malignant
cells [47].
It is obvious that the metastasis potential of a
malignant cell depends on specificities of the proteome,
sorting and segregation of proteins and the possibility
for the latter to realize a wide spectrum of intercellular
interactions. On the one hand, the increased levels of
u-PA and u-PAR on the membranes of malignant cells
are considered to be negative prognostic parameters
during cancer, since Pm induces angiogenesis and the
invasion of cells through cleaving proteins of extra-
cellular matrix and activating metalloproteinase. On the
other hand, Pm is the source for AS (however, only in
case of combined exposure of u-PA, u-PAR and actin
on the cell surface).
Current literature data give reason to consider
surface actin as an additional prognostic indicator, the
level of which can be in positive correlation with the
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suppression of tumor growth and prolonging the
patients’ lifespan.
Thus, the mentioned interaction between two mul-
tifunctional protein systems may to some extent explain
the paradigm: why Pm as an inductor of angiogenesis
causes local effects, while AS inhibit the angiogenesis
systemically. Further study of the mechanisms of pro-
tein-protein interactions of the components of Pg/Pm
system with membrane-associated ligands, including
surface actin, should be carried out to understand the
properties of the functioning of fibrinolytic system
proteins in non-hemostatic processes.
Considering all the abovementioned, the elabora-
tion of approaches, aimed at the actin exposure by ma-
lignant cells as an additional center of AS generation,
endogenous inhibitors of tumor growth and metastasis,
is believed to be a promising perspective.
Interaction of Pg/Pm system with actin on the
surface of catecholamine-producing cells. The sym-
patoadrenal system regulates all processes in organism
at different stages of its ontogenesis. The mediators of
the sympathoadrenal system include catecholamines:
noradrenaline (norepinephrine), adrenaline (epine-
phrine) and dopamine, mainly synthesized by chrom-
affin cells of adrenal medulla and adrenergic neurons of
CNS and sympathetic ganglia. Their synthesis and
secretion are the subject to strict control of the
neuroendocrine system, implemented by a number of
hormone-like substances of peptide nature [64]. All the
inductors and inhibitors of catecholamine release are
synthesized in the form of inactive prohormones, the
mechanisms of processing of which are still obscured.
It is known that protein chromogranin A (Cg A),
present in many cells of the neuroendocrine system, is
the precursor of a number of tissue-specific peptides
that modulate secretory function of cells [65]. The
initial studies of CgA processing revealed that it is the
most active in the presence of chromaffin cells [66.]
These researches supposed that the hormone-producing
cells synthesize [the] substances that regulate levels of
peptides, modulating the release of catecholamines via
the negative feedback mechanism. However, the nature
of enzymes in catecholaminergic cells, performing the
limited proteolysis of CgA, remained unknown for a
long time. It has been previously discovered that both
bacterial endoproteinase LysC and trypsin (the enzy-
mes that are not inherent for extracellular medium of
chromaffin cells) are able to cleave CgA specifically at
the hydrolysis site, which coincides with that for Pm,
and Pm zymogene is present in extracellular matrix of
these cells [67, 68]. This fact formed the basis of the
hypothesis, which was experimentally confirmed later,
that Pm is the most important protease, responsible for
the inhibition of catecholamine release by means of
CgA processing. The mechanism (Fig. 2) of CgA
cleavage by Pm with the formation of physiologically
active peptides, capable of inhibiting the secretion of
catecholamines in response to acetylcholine stimula-
tion of pheochromocytoma cells PC12 and chromaffin
cells of bovine adrenal medulla [18, 67], has been re-
cently discovered. At the first stage, Pg is bound to the
cell surface in several sites, including high affine site
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Fig. 1 The scheme of the formation of angiostatin K1-4,5 (AS 4,5) as a result of plasmin autoproteolisys (Pm), mediated by actin exposed on the
outer surface of the plasma membrane (p.m.) of tumor cell: I – binding of plasminogen (Pg) with surface actin in the vicinity of activator (u-PA)
and its receptor (u-PAR); II, III – recognition of Pg molecule by the activator and conversion of the latter into Pm; IV – Pm autoproteolisys
followed by releasing of fragments: KI-4,5 (AS 4,5) and microplasmin (m-Pm) (according to the data of [7, 47])
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(Kd = 77 nM). The second stage of the process consists
in activation of membrane-bound Pg with the parti-
cipation of t-PA, which, in turn, is secreted by the chro-
maffin cells in response to stimulation.
The authors of these experiments established a cru-
cial role of Pg interaction with the cellular membrane:
firstly, this event is required for conformational chan-
ges in the zymogene molecule; secondly, as stated abo-
ve, the membrane-bound Pm is protected from 2-anti-
plasmin-induced inhibition.
The nature of proteins, the potential receptors of Pg
on the surface of catecholaminergic cells, was analyzed
using two-dimensional electrophoresis, radioligand-
blotting and tandem mass-spectrometry, established
that the extracellular - and -isomers of actin (9.8·104
per cell in average) are responsible for Pg interaction
with plasma membrane. Some experiments also de-
monstrated direct involvement of surface actin in pro-
tein processing and showed that incubation of chrom-
affin cell culture with anti-actin antibodies leads to
parallel decrease in level of Pg activation and enhan-
cement of norepinephrine release. The inhibitory
effects of 6-AHA on Pg binding to actin in the cell
culture support participation of LBS of Pg kringle
domains and lysine residues in the actin molecule in
intermolecular interaction. The treatment of cells with
carboxypeptidase C was observed to decrease the Pg
activation level by 90 %; this indicates that C-terminal
lysine residues (most likely Lys373) in partially split
actin are involved into interaction with Pg [18].
The functioning of complex of Pg activation system
in concert with extracellular actin on the surface of ca-
techolaminergic cells might play a key role in the mo-
dulation of secretion of biologically active compounds.
It should be noted that Pg and the components of its
activation system were also found in other neuroen-
docrine structures, including neurons of brain cortex,
cerebellum, hippocampus as well as cells of peripheral
nervous system [35, 69, 70]. It is possible that the
described interaction of Pg/Pm system with surface
actin could be a universal mechanism for the regulation
of neurosecretory activity of adrenergic cells in both the
central and peripheral nervous systems.
Conclusions. Plasminogen/plasmin and actin are
the examples of multifunctional interoperable proteins.
Taking into consideration the “ubiquity” of actin, it is
assumed that this protein, located on the surface of the
plasmatic membrane of cells, may serve as a universal
modulator of the plasminogen/plasmin system activity.
Actin induces conformational changes in Pm molecule,
which modify the enzyme activity and substrate spe-
cificity. In the complex with the surface actin, plasmin
is involved in processing of biologically active peptides
or subjected to autoproteolysis with the formation of
angiostatin, a powerful endogenous inhibitor of neo-
vascularization and metastasis. Investigation of signa-
ling mechanisms with the participation of the compo-
nents of plasminogen/plasmin system and actin is con-
sidered to be a significant fundamental issue and a pro-
mising perspective for the elaboration of new approa-
ches to diagnostics and therapy of various disorders, in
particular, thrombotic states, cancer and pathologies of
the nervous system.
Chromaffin granule
Actin
+
Pg
t-PA
Agonist
-
Cats
CgAt-PA
CgA
Pm
Catecholamines
(Cats)
T-PA
Cg-A
Proteolytic fragments
CgA st
Fig. 2 The mechanism of chromogranin A processing (CgA) induced
by plasmin (Pm) on the membrane of catecholamine-producing cells.
Circulating plasminogen (Pg) is bound to surface actin and converted
into plasmin with the participation of t-PA, located on the membrane
receptor. CgA is accumulated in chromaffin granules together with
t-PA and catecholamines and secreted by the cells in response to
stimulation, and then fragmented by Pm. Proteolytic fragments of CgA
inhibit secretion and releasing of catecholamines by virtue of negative
feedback mechanism (according to the data of [18, 67]).
À. Î. Òèõîìèðîâ
Âçàºìîä³ÿ àêòèíó ç ïëàçì³íîãåí/ïëàçì³íîâîþ ñèñòåìîþ:
ìåõàí³çìè òà ô³ç³îëîã³÷íà ðîëü
²íñòèòóò á³îõ³ì³¿ ³ì. Î. Â. Ïàëëàä³íà ÍÀÍ Óêðà¿íè
Âóë. Ëåîíòîâè÷à, 9, Êè¿â, Óêðà¿íà, 01601
Ðåçþìå
Â îãëÿä³ âïåðøå ïðîàíàë³çîâàíî òà óçàãàëüíåíî ë³òåðàòóðí³ äàí³
ñòîñîâíî êîîïåðàö³¿ ìóëüòèôóíêö³îíàëüíèõ á³ëê³â: êîìïîíåíò³â
ñèñòåìè ïëàçì³íîãåí/ïëàçì³íó òà àêòèíó. Ðîçãëÿíóòî ìåõàí³çìè,
ùî ëåæàòü â îñíîâ³ ì³æìîëåêóëÿðíèõ âçàºìîä³é, òà ðîëü êðèí-
ãëîâèõ äîìåí³â ïëàçì³íîãåíó ó ì³æá³ëêîâîìó ðîçï³çíàâàíí³. Îñîá-
ëèâó óâàãó ïðèä³ëåíî åêñòðàöåëþëÿðíîìó àêòèíó, ÿêèé âèêîíóº
ôóíêö³¿ á³ëêà ïîâåðõí³ ïëàçìàòè÷íî¿ ìåìáðàíè ð³çíèõ êë³òèí.
Îáãîâîðþºòüñÿ ìîæëèâà ðîëü ïîâåðõíåâîãî àêòèíó ÿê óí³âåð-
ñàëüíîãî «íåãåìîñòàòè÷íîãî» öåíòðà àêòèâàö³¿ ïëàçì³íîãåíó, à
òàêîæ ôóíêö³îíàëüíå çíà÷åííÿ åêñïîíóâàííÿ öèòîñêåëåòíîãî
á³ëêà ð³çíèìè êë³òèíàìè çà íîðìàëüíèõ ô³ç³îëîã³÷íèõ óìîâ òà ïðè
ðîçâèòêó ïà- òîëîã³é. Çîêðåìà, îïèñàíî ìåõàí³çì ôðàãìåíòàö³¿
ïëàçì³íîãåíó íà ïîâåðõí³ ðàêîâèõ êë³òèí çà ó÷àñò³ àêòèíó ç óòâî-
ðåííÿì åíäîãåííèõ ñóïðåñîð³â ïóõëèííîãî ðîñòó òà ìåòàñòàçó-
âàííÿ – àíã³îñòàòèí³â ³ çàëó÷åííÿ ñèñòåìè ïëàçì³íîãåí/ïëàçì³í
òà ïîâåðõíåâîãî àêòèíó äî ðåãóëÿö³¿ ðåë³çèíãó á³îëîã³÷íî àêòèâ-
íèõ ðå÷îâèí íà ïðèêëàä³ êàòåõîëàì³íïðîäóêóþ÷èõ êë³òèí. Êîì-
ïëåêñíà îö³íêà ñòàíó ïëàçì³íîãåí/ïëàçì³íîâî¿ ñèñòåìè òà àêòè-
íó ïðîïîíóºòüñÿ ÿê êðèòåð³é ôóíêö³îíàëüíîãî ñòàòóñó êë³òèí,
ùî ìîæå çíàéòè çàñòîñóâàííÿ ó ä³àãíîñòèö³ ð³çíèõ ïàòîëîã³é.
Êëþ÷îâ³ ñëîâà: ìóëüòèôóíêö³îíàëüí³ á³ëêè, ñèñòåìà ïëàç-
ì³íîãåí/ïëàçì³í, àêòèí.
À. À. Òèõîìèðîâ
Âçàèìîäåéñòâèå àêòèíà ñ ïëàçìèíîãåí/ïëàçìèíîâîé ñèñòåìîé:
ìåõàíèçìû è ôèçèîëîãè÷åñêàÿ ðîëü
Ðåçþìå
Â îáçîðå âïåðâûå ïðîàíàëèçèðîâàíû è îáîáùåíû ëèòåðàòóðíûå
äàííûå îòíîñèòåëüíî êîîïåðàöèè ìóëüòèôóíêöèîíàëüíûõ áåë-
êîâ: êîìïîíåíòîâ ïëàçìèíîãåí/ïëàçìèíîâîé ñèñòåìû è àêòèíà.
Ðàññìîòðåíû ìåõàíèçìû, ëåæàùèå â îñíîâå ìåæìîëåêóëÿðíûõ
âçàèìîäåéñòâèé, è ðîëü êðèíãëîâûõ äîìåíîâ ïëàçìèíîãåíà â ìåæ-
áåëêîâîì ðàñïîçíàâàíèè. Îñîáîå âíèìàíèå óäåëåíî ýêñòðàöåëëþ-
ëÿðíîìó àêòèíó, âûïîëíÿþùåìó ôóíêöèè áåëêà ïîâåðõíîñòè ïëàç-
ìàòè÷åñêîé ìåìáðàíû ðàçëè÷íûõ êëåòîê. Îáñóæäàåòñÿ âîçìîæ-
íàÿ ðîëü ïîâåðõíîñòíîãî àêòèíà êàê óíèâåðñàëüíîãî «íåãåìîñòà-
òè÷åñêîãî» öåíòðà àêòèâàöèè ïëàçìèíîãåíà, à òàêæå ôóíêöèî-
íàëüíîå çíà÷åíèå ýêñïîíèðîâàíèÿ öèòîñêåëåòíîãî áåëêà ðàçíûìè
êëåòêàìè ïðè íîðìàëüíûõ ôèçèîëîãè÷åñêèõ óñëîâèÿõ è ðàçâèòèè
ïàòîëîãèé. Â ÷àñòíîñòè, îïèñàí ìåõàíèçì ôðàãìåíòàöèè ïëàç-
ìèíîãåíà íà ïîâåðõíîñòè ðàêîâûõ êëåòîê ïðè ó÷àñòèè àêòèíà ñ
îáðàçîâàíèåì ýíäîãåííûõ ñóïðåññîðîâ îïóõîëåâîãî ðîñòà è ìåòà-
ñòàçèðîâàíèÿ – àíãèîñòàòèíîâ è âîâëå÷åíèå ñèñòåìû ïëàçìèíî-
ãåí/ïëàçìèí è ïîâåðõíîñòíîãî àêòèíà â ðåãóëÿöèþ ðåëèçèíãà áèî-
ëîãè÷åñêè àêòèâíûõ âåùåñòâ íà ïðèìåðå êàòåõîëàìèíïðîäóöè-
ðóþùèõ êëåòîê. Êîìïëåêñíàÿ îöåíêà ñîñòîÿíèÿ ïëàçìèíîãåí/
ïëàçìèíîâîé ñèñòåìû è àêòèíà ïðåäëàãàåòñÿ â êà÷åñòâå êðèòå-
ðèÿ ôóíêöèîíàëüíîãî ñîñòîÿíèÿ êëåòîê è ìîæåò íàéòè ïðèìå-
íåíèå â äèàãíîñòèêå ðàçëè÷íûõ ïàòîëîãèé.
Êëþ÷åâûå ñëîâà: ìóëüòèôóíêöèîíàëüíûå áåëêè, ñèñòåìà ïëàç-
ìèíîãåí/ïëàçìèí, àêòèí.
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